Antimicrobial Agents and Chemotherapy · 2019 · 26 citations · 25 references
PharmacyPharmacokineticsPharmacologyAntimicrobial PharmacotherapyPharmacokinetic ModelingPharmacokinetic-pharmacodynamic ModelingAntimicrobial DosingChemotherapy Dose CalculationDose OptimizationPharmacokinetics Of AntimicrobialsPopulation Pharmacokinetic-pharmacodynamic ModelingTuberculosis PharmacotherapyCulture Conversion MonitoringFluoroquinolone-based RegimensPharmacodynamic Target AttainmentPharmacodynamics Of Antitubercular DrugsSputum MicrobiologyTreatment Dosing RegimensTuberculosis Drug ResistanceTuberculosis Treatment Regimens
= 0.012). After adjusting for isoniazid and clofazimine treatment, patients treated with new-generation fluoroquinolones were more likely to have culture conversion (adjusted hazards ratio, 2.16 [95% confidence interval, 1.28 to 3.64]). We included 178 patients in the pharmacokinetic models. Levofloxacin and moxifloxacin were best described by a one-compartment model with first-order absorption and elimination. At least 1,500 to 1,750 mg levofloxacin and 800 mg moxifloxacin may be needed for maximum kill at the current epidemiologic cutoff values. In summary, new-generation fluoroquinolones showed faster time to culture conversion compared to the old generation. For optimal target attainment at the current MIC values, higher doses of levofloxacin and moxifloxacin may be needed.
25
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis
Andrew Nunn, Patrick Phillips, Sarah Meredith et al. · New England Journal of Medicine · 2019 · 402 citations · Full text
Tawanda Gumbo, Arnold Louie, Mark R. Deziel et al. · The Journal of Infectious Diseases · 2004 · 317 citations
Ekaterina V. Kurbatova, J. Peter Cegielski, Christian Lienhardt et al. · The Lancet Respiratory Medicine · 2015 · 158 citations · Full text
Tuberculosis origin: The Neolithic scenario
Israël Hershkovitz, Helen D. Donoghue, David E. Minnikin et al. · Tuberculosis · 2015 · 147 citations · Full text